Pharma Boardroom Interview
Interview for Pharma Boardroom, discussing the Institute Gulbenkian de Ciência – Fundação Calouste Gulbenkian.
Similar Posts
The Diagnostic Timing Trap
“70% of clinical decisions depend on diagnostics.” You’ve seen this statistic, but it hides an important detail: timing. The acuity gradient: Lab testing occurs in 98% of inpatient encounters, 56% in emergency departments, but only 29% in outpatient settings (Ngo et al., 2017): diagnostics concentrate where disease is most advanced. Prevention is neglected: Evidence-based guidelines…
A genómica dos tumores sólidos e o papel da biópsia tissular e líquida
A GENÓMICA DOS TUMORES SÓLIDOS E O PAPEL DA BIÓPSIA TISSULAR E LÍQUIDA O cancro é considerado uma doença genómica, em que alterações no ADN do tumor geram uma multiplicação descontrolada das células. Este comportamento invasivo origina a metastização e a resistência a fármacos tornando a terapêutica ineficaz…
Who will lead the adoption of an IoT/Robotic/AI medicine?
I have had this conversation over and over again, so I decided to lay out some arguments here. I am convinced that we are on the brink of a major change in the way medicine is practiced for two reasons. The first, which I will leave for another occasion is the empowerment of the individual…
Interview/Debate – Falar Global
At the Falar Global show, discussing with Reginaldo Rodrigues de Almeida new technologies in medicine, like genomics and bioinformatics, and the future (and present) of medicine
Genealogia “tech”: recursos digitais e ideias de negócio
Muitos saberão que eu tenho o vício da genealogia. Para os que pública ou discretamente o partilham, deixo uma informação útil. Os 12 volumes da obra Portugal Antigo e Moderno – de Pinho Leal foram digitalizado pela Universidade de Toronto. Também o Portugal Sacro -Profano, de Paulo Dias de Niza foi digitalizado. Estes são catálogos…
The 60-Million+ Patient Passport: Why the GCC Needs a “Gulf CE Mark”
Published on LinkedIn on Dec 1st, 2025 In the global race for medical innovation, market size matters, but market access matters more. Today, a medical device manufacturer targeting the Gulf Cooperation Council (GCC) faces a paradoxical reality. They (we!) see a wealthy, integrated economic bloc of 60+ million people with world-class healthcare infrastructure. Yet, when…